Hospital morbidity associated with the natural history of heroin use

Robert J. Tait, PhD, BSc (Hons); Gary K. Hulse, PhD, BBSc (Hons)

doi:10.5055/jom.2008.0036

Authors

Robert J. Tait, PhD, BSc (Hons)
Gary K. Hulse, PhD, BBSc (Hons)

DOI:

https://doi.org/10.5055/jom.2008.0036

Keywords:

heroin, hospital, naltrexone, morbidity

Abstract

Objective: To assess changes in hospital morbidity associated with heroin use from pre-initiation, recreational to dependent use, and changes following treatment.
Design: Analysis of hospital admission data assessed over six, 6-month periods (before and after heroin initiation; two dependent heroin use periods; and post-oral and post-sustained release naltrexone treatment).
Participants: A sequential cohort of 139 patients for whom date of initial heroin use, regular heroin use, and two periods of heroin dependence (prior to treatment with oral and implant naltrexone) were known.
Outcome Measures: The West Australian Data Linkage System was used to assemble hospital admission data. Admissions were analyzed as follows: “all cause” admissions and then subgrouped as “mental health (MH) other,” “MH opioid related,” “MH non-opioid drug related,” and “opioid overdoses.”
Results: The database identified 130 (94 percent) of the participants with 76 (59 percent) being male. The mean length of follow-up from first heroin use was 9.4 (SD 4.9) years. Significant increases in morbidity were not found in the periods pre-first and post-first heroin use, but were found from pre-heroin use to dependent use for “all cause,” “MH opioid related,” and “opioid overdose” admissions. A significant decline in these measures was observed from the first dependent period to the post-implant period. “MH opioid related” admissions declined from the first to the second period of dependent heroin use.
Conclusions: Findings suggest that the movement to dependent heroin use increases hospital morbidity; that morbidity in the presence of treatment does not necessarily increase; and the treatment with a sustained release preparation may be more effective than oral naltrexone in arresting morbidity.

Author Biographies

Robert J. Tait, PhD, BSc (Hons)

School of Psychiatry and Clinical Neurosciences, University of Western Australia, QE II Medical Centre, Nedlands, Western Australia.

Gary K. Hulse, PhD, BBSc (Hons)

School of Psychiatry and Clinical Neurosciences, University of Western Australia, QE II Medical Centre, Nedlands, Western Australia.

References

Hulse GK, English DR, Milne E, et al.: The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999; 94: 221-229.

Warner-Smith M, Darke S, Day C: Morbidity associated with non-fatal heroin overdose. Addiction. 2002; 97: 963-967.

Hulse GK, Basso MR, Wodak A: The injecting drug user. In Hulse GK, White Jason M, Cape G, (eds.): Management of Alcohol and Drug Problems. Melbourne: Oxford University Press; 2002: 241-257.

Darke S, Sims J, McDonald S, et al.: Cognitive impairment among methadone maintenance patients. Addiction. 2000; 95: 687-695.

Gossop M, Marsden J, Stewart D, et al.: The National Treatment Outcome Research Study (NTORS): 4-5 year followup results. Addiction. 2003; 98: 291-303.

Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mt Sinai J Med. 2000; 67: 347-364.

Stewart D, Gossop M, Marsden J. Reductions in non-fatal overdose after drug misuse treatment: Results from the National Treatment Outcome Research Study (NTORS). J Subst Abuse Treat. 2002;22:1-9.

Henderson N, Ross J, Darke S, et al.: Longitudinal studies of dependent heroin users in Australian: Feasibility and benefits. Australia: National Drug and Alcohol Research Centre, 2002.

Darke S, Hall W: Heroin overdose: Research and evidence based intervention. J Urban Health. 2003; 80: 189-200.

Darke S, Ross J, Hall W: Overdose among heroin users in Sydney, Australia. I. Prevalence and correlates of non-fatal overdose. Addiction. 1996; 91: 405-411.

Hser Y-L, Hoffman V, Grella CE, et al.: A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001; 58: 503-508.

Hulse GK, Tait RJ, Comer SD, et al.: Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 2005; 79: 351-357.

Ngo H, Tait R, Arnold-Reed D, et al.: Mental health outcomes following naltrexone implant treatment for heroin dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 605-612.

Ngo HTT, Tait RJ, Hulse GK: Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implant. Arch Gen Psychiatry. 2008; 65: 457-465.

Tait RJ, Ngo HTT, Hulse GK. Mortality in heroin users three years post implant naltrexone or methadone maintenance treatment. J Subst Abuse Treat. 2008; 35: 116-124.

Hulse GK, Basso MR: The association between naltrexone compliance and daily supervision. Drug Alcohol Rev. 2000; 19: 41-48.

Hulse GK, Arnold-Reed DE, O’Neil G, et al. Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: Comparing two naltrexone implants. Addict Biol. 2004; 9: 59-65.

Ngo HT, Arnold-Reed DE, Hansson RC, et al.: Blood naltrexone levels over time following naltrexone implants. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 23-28.

Comer SD, Collins ED, Kleber HD, et al.: Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002; 159: 351-360.

Navaratnam V, Jamaludin A, Raman N, et al.: Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts. Drug Alcohol Depend. 1994; 34: 231-236.

Chiang CN, Hollister LE, Gillespie HK, et al.: Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend. 1985; 16: 1-8.

Holman CDJ, Bass AJ, Rouse IL, et al.: Population-based linkage of health records in Western Australia: Development of a health services research linked database. Aust N Z J Pub Health. 1999; 23: 453-459.

Lawrence D, Holman CD, Jablenski A, et al.: Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry. 2003; 182: 31-36.

Valinsky LJ, Hockey RL, Hobbs MS, et al.: Finding bile duct injuries using record linkage: A validated study of complications following cholecystectomy. J Clin Epidemiol. 1999; 52: 893-901.

Data Linkage Unit, Statistical Summary. Available at http://www.publichealth.uwa.edu.au/welcome/research/dlu/linkage/stats. Accessed May 9, 2005.

Therapeutic Goods Administration: Access to Unapproved Therapeutic Goods–The Special Access Scheme (SAS). Canberra: Commonwealth Department of Health and Aged Care, 2001.

World Health Organization: International Classification of Diseases and Health Related Problems: 10th Revision. Geneva: WHO, 1992.

World Health Organization: International Classification of Diseases and Health Related Problems: 9th Revision: Clinical Modification. Geneva: WHO; 1986.

World Health Organization: International Classification of Diseases, 9th Revision. Geneva: WHO; 1977.

Kaya C, Tugai Y, Filar J, et al.: Heroin users in Australia: Population trends. Drug Alcohol Rev. 2004;23:107-116.

Catalano RF, Hawkins JD, Wells EA, et al.: Evaluation of the effectiveness of adolescent drug abuse treatment, assessment of risks for relapse, and promising approaches for relapse prevention. Int J Addict. 1990; 25: 1085-1140.

Brewer DD, Catalano RF, Haggerty K, et al.: A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction [Review]. Addiction. 1998; 93: 73-92.

DiClemente C: Motivational interviewing and the stages of change. In Miller WR, Rollnick S (eds.): Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press; 1991: 191-202.

Verebey K, Volavka J, Mule SJ, et al.: Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther. 1976; 20: 315-328.

Darke S, Ross J, Zador D, et al.: Heroin-related deaths in New South Wales, Australia, 1992-1996. Drug Alcohol Depend. 2000; 60: 141-150.

McGregor C, Darke S, Ali R, et al.: Experience of non-fatal overdose among heroin users in Adelaide, Australia–Circumstances and risk perceptions. Addiction. 1998; 93: 701-711.

Hulse GK, Tait RJ: A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in ‘high risk’ adolescent heroin users. Addict Biol. 2003; 8: 337-342 .

Longo MC, Henry-Edwards SM, Humeniuk RE, et al.: Impact of the heroin ‘drought’ on patterns of drug use and drug-related harms. Drug Alcohol Rev. 2004; 23: 143-150.